NKTR

Nektar Therapeutics · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-13

Figures on this page computed 2026-11-08 12:40 UTC

Last close

38.48USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-13

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-13
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
- 10-K for 2025, filed 2026-03-13
- 10-K for 2025, filed 2026-03-13
- 10-K for 2025, filed 2026-03-13
- 10-Q for 2025, filed 2026-08-14
- 10-K for 2025, filed 2026-03-13
- 10-Q for 2025, filed 2026-08-14
The filing itself
-297.1%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
- 10-K for 2025, filed 2026-03-13
- 10-K for 2025, filed 2026-03-13
The filing itself
-377.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
- 10-K for 2025, filed 2026-03-13
- 10-K for 2025, filed 2026-03-13
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
- 10-K for 2025, filed 2026-03-13
- 10-Q for 2025, filed 2026-08-14
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.16 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.23x

0.86x

1.39x

n/a

0.15x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-13

Sales0.23x
Its own average over 10 years, 237.2M.
Profit0.86x
Its own average over 10 years, -190.5M.
Free cash flow1.39x
Its own average over 10 years, -150.2M.
Debtn/a
Its own average over 0 years.
Price0.15x
Its own average over 11 years, 254. Market data, 2026-11-04

Price is furthest from its own average, at 0.15 times.

Sales is 0.23 times its own 10-year average; Profit is 0.86 times its own 10-year average; Free cash flow is 1.39 times its own 10-year average; Price is 0.15 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-13

Sales against its own 10-year average0.23
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
The filing itself
Profit against its own 10-year average0.86
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
The filing itself
Free cash flow against its own 10-year average1.39
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
The filing itself
Debt against its own 0-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-104547
Reported in
USD
The filing itself
Price against its own 11-year average0.15Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD